1. Mattson, CL, Tanz, LJ, Quinn, K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths – United States, 2013-2019. MMWR Morb Mortal Wkly Rep 2021; 70: 202–207.
Google Scholar | Crossref | Medline2. Gladden, RM, O’Donnell, J, Mattson, CL, et al. Changes in the opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine – 25 states, July-December 2017 to January-June 2018. MMWR Morb Mortal Wkly Rep 2019; 68: 737–744.
Google Scholar | Crossref | Medline3. Department of Justice Office of Public Affairs . Opioid manufacturer Purdue Pharma pleads guilty to fraud and kickback conspiracies, www.justice.gov/opa/pr/opioid-manufacturer-purdue-pharma-pleads-guilty-fraud-and-kickback-conspiracies (2020, accessed 5 March 2021).
Google Scholar4. Substance Abuse and Mental Health Services Administration . Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. HHS Publication No. PEP20-07-01-001, NSDUH Series H-55. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, September 2020.
Google Scholar5. United Nations Office on Drugs and Crime. World drug report 2015. Report for the United Nations. Report no. E.15.XI.6. Vienna: AT, May 2015.
Google Scholar6. Dasgupta, N, Beletsky, L, Ciccarone, D. Opioid crisis: no easy fix to its social and economic determinant. Am J Public Health 2018; 108: 182–186.
Google Scholar | Crossref | Medline7. Hawkins, D, Punnett, L, Davis, L, et al. The contribution of occupation-specific factors to the deaths of despair, Massachusetts, 2005-2015. Ann Work Expo Health. Epub ahead of print 23 April 2021. DOI: 10.1093/annweh/wxab017.
Google Scholar8. National Opinion Research Center at the University of Chicago and National Safety Council . Substance use disorders by occupation, www.nsc.org/getmedia/9dc908e1-041a-41c5-a607-c4cef2390973/substance-use-disorders-by-occupation.pdf (n.d., accessed 15 March 2021).
Google Scholar9. Hagemeier, NE. Introduction to the opioid epidemic: the economic burden on the healthcare system and impact on quality of life. Am J Manag Care 2018; 24: S200–S206.
Google Scholar | Medline10. Florence, C, Luo, F, Rice, K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend 2021; 218: 108350.
Google Scholar | Crossref | Medline11. Co, C, Rae, M. A look at how the opioid crisis has affected people with employer coverage. Peterson-KFF Health System Tracker, www.healthsystemtracker.org/brief/a-look-at-how-the-opioid-crisis-has-affected-people-with-employer-coverage/ (2018, accessed 10 March 2021).
Google Scholar12. National Safety Council. Opioids and the workplace , www.nsc.org/getmedia/47e44256-f6fb-486d-9df3-256fbc9df53e/opioids-in-the-workplace.pdf.aspx (2019, accessed 16 March 2021).
Google Scholar13. Frone, M. Alcohol and illicit drug use in the workforce and workplace. 1st ed. Washington, DC: American Psychological Association, 2012, p.31.
Google Scholar14. Hawkins, D, Roelofs, C, Laing, J, et al. Opioid-related overdose deaths by industry and occupation-Massachusetts, 2011-2015. Am J Ind Med 2019; 62: 815–825.
Google Scholar | Crossref | Medline15. Kowalski-McGraw, M, Green-McKenzie, J, Pandalai, S, et al. Characterizing the interrelationships of prescription opioids and benzodiazepine drugs with worker health and workplace hazards. J Occup Environ Med 2017; 59: 1114–1126.
Google Scholar | Crossref | Medline16. Shaw, WS, Roelofs, C, Punnett, L. Work environment factors and prevention of opioid-related deaths. Am J Public Health 2020; 110: 1235–1241.
Google Scholar | Crossref | Medline17. Dong, XS, Brooks, R, Brown, S. Musculoskeletal disorders and prescription opioid use among U.S. construction workers. J Occup Environ Med 2020; 62: 973–979.
Google Scholar | Crossref | Medline18. Injury Facts . Top work-related injury causes, https://injuryfacts.nsc.org/work/work-overview/top-work-related-injury-causes/ (2021, accessed 20 March 2021).
Google Scholar19. Occupational Safety and Health Administration . Ergonomics, www.osha.gov/ergonomics (n.d., accessed 20 March 2021).
Google Scholar20. Arnautovic, N. Workers compensation and prescription drugs – 2018 update. Report, National Council on Compensation Insurance, USA, January 2019.
Google Scholar21. Haight, JR, Sears, JM, Fulton-Kehoe, D, et al. Early high-risk opioid prescribing practices and long-term disability among injured workers in Washington State, 2002 to 2013. J Occup Environ Med 2020; 62: 538.
Google Scholar | Crossref | Medline22. Hunt, DL, Artuso, RD, Kalia, N, et al. Association of opioid, anti-depressant, and benzodiazepines with workers’ compensation cost a cohort study. J Occup Environ Med 2019; 61: e206–e211.
Google Scholar | Crossref | Medline23. Harnois, G, Gabriel, P, et al. World Health Organization ,. Mental health and work: impact, issues and good practices. Report for the World Health Organization. Report no. WHO/MSD/MPS/00.2, 2000. Geneva: WHO.
Google Scholar24. Choi, B. Opioid use disorder, job strain, and high physical job demands in US workers. Int Arch Occup Environ Health 2020; 93: 577–588.
Google Scholar | Crossref | Medline25. Goplerud, E, Hodge, S, Benham, T. A substance use cost calculator for US employers with an emphasis on prescription pain medication misuse. J Occup Environ Med 2017; 59: 1063–1071.
Google Scholar | Crossref | Medline26. National Opinion Research Center at the University of Chicago, National Safety Council . A substance use cost calculator for U.S. employers: overview of data sources and analytic approach, www.nsc.org/getmedia/822b3672-38a9-4b0a-8c06-a1953a18060c/succ-methodology.pdf (n.d., accessed 15 March 2021).
Google Scholar27. National Opinion Research Center at the University of Chicago, National Safety Council . How workers with active substance use disorders impact employer health care costs, www.nsc.org/getmedia/a3ed3b0d-e6bb-459b-984d-8cf7380cd713/sud-costs.pdf (n.d., accessed 15 March 2021).
Google Scholar28. Ahmad, FB, Rossen, LM, Sutton, P. Provisional drug overdose death counts. National Center for Health Statistics, www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (2021, accessed 20 March 2021).
Google Scholar29. CDC Health Alert Network . Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic, https://emergency.cdc.gov/han/2020/han00438.asp (2020, accessed 17 December 2020).
Google Scholar30. American Medical Association . Issue brief: Reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic, www.ama-assn.org/system/files/2020-12/issue-brief-increases-in-opioid-related-overdose.pdf (2021, accessed 3 March 2021).
Google Scholar31. Dubey, MJ, Ghosh, R, Chatterjee, S, et al. COVID-19 and addiction. Diabetes Metab Syndr 2020; 14: 817–823.
Google Scholar | Crossref | Medline32. Hulsey, J, Mellis, A, Kelly, B. COVID-19 pandemic impact on patients, families and individuals in recovery from substance use disorders. Report, Addiction Policy Forum, USA, June 2020.
Google Scholar33. Nagelhout, GE, Hummel, K, De Goeij, MCM, et al. How economic recessions and unemployment affect illegal drug use: a systematic realist literature review. Int J Drug Policy 2017; 44: 69–83.
Google Scholar | Crossref | Medline | ISI34. Czeisler, MÉ, Lane, RI, Petrosky, E, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic – United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1049–1057.
Google Scholar | Crossref | Medline35. Gagnon, L, Thompson, M, McHugh, C, et al. Mental health index: U.S. worker edition. Powerpoint presented at National Alliance of Healthcare Purchaser Coalitions, 2020.
Google Scholar36. Adams, T, Reinert, M, Fritze, D, et al. Mind the workplace. Report, Mental Health America, USA, February 2021.
Google Scholar37. NIDA . Part 1: the connection between substance use disorders and mental illness. Report, National Institute on Drug Abuse, USA, April 2021.
Google Scholar38. CDC COVID-19 Response Team . Characteristics of health care personnel with COVID-19 – United States, February 12-April 9, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 477–481.
Google Scholar | Crossref | Medline39. Chen, YH, Glymour, M, Riley, A, et al. Excess mortality associated with the COVID-19 pandemic among Californians 18-65 years of age, by occupational sector and occupation: March through November 2020. PloS One 2021; 16: e0252454.
Google Scholar | Medline40. Boyd, G. The drug war is the new Jim Crow. NACLA, https://nacla.org/article/drug-war-new-jim-crow (2007, accessed 7 May 2021).
Google Scholar41. Netherland, J, Hansen, HB. The war on drugs that wasn’t: wasted whiteness, “dirty doctors,” and race in media coverage of prescription opioid misuse. Cult Med Psychiatry 2016; 40: 664–686.
Google Scholar | Crossref | Medline | ISI42. Rosino, ML, Hughey, MW. The war on drugs, racial meanings, and structural racism: a holistic and reproductive approach. Am J Econ Sociol 2018; 77: 849–892.
Google Scholar | Crossref43. Volkow, ND, Jones, EB, Einstein, EB, et al. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry 2019; 76: 208–216.
Google Scholar | Crossref | Medline44. Drug Policy Alliance. The drug war, mass incarceration and race , https://drugpolicy.org/resource/drug-war-mass-incarceration-and-race-englishspanish (2018, accessed 20 March 2021).
Google Scholar45. Kurbin, CE, Squires, G, Stewart, E. Neighborhoods, race, and recidivism: the community reoffending nexus and its implications for African Americans. Sage Race Relat Abstr 2007; 32: 7–37.
Google Scholar | Crossref46. Boserup, B, McKenney, M, Elkbuli, A. Disproportionate impact of COVID-19 pandemic on racial and ethnic minorities. Am Surg 2020; 86: 1615–1622.
Google Scholar | SAGE Journals47. Rosen, J, Harnett, P. Confronting two crises: the COVID-19 pandemic, the opioid epidemic, and the industrial hygienist. New Solut. Epub ahead of print 7 July 2021. DOI: 10.1177/10482911211029580.
Google Scholar48. Centers for Disease Control and Prevention. Health equity considerations and racial and ethnic minority groups , www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html (2021, accessed 21 March 2021).
Google Scholar49. Yancy, CW. COVID-19 and African Americans. JAMA 2020; 323: 1891–1892.
Google Scholar | Crossref | Medline50. Shannon, CA, Rospenda, KM, Richman, JA, et al. Race, racial discrimination, and the risk of work-related illness, injury or assault: findings from a national study. J Occup Environ Med 2009; 51: 441–448.
Google Scholar | Crossref | Medline51. Gilbert, KL, Ray, R. A colorblind vaccine approach isn’t good enough. The US needs racial equity, www.theguardian.com/commentisfree/2021/feb/09/vaccine-gerrymandering-coronavirus-racial-equity (2021, accessed 1 April 2021).
Google Scholar52. Ndugga, N, Artiga, S, Pham, O. How are states addressing racial equity in COVID-19 vaccine efforts?. Kaiser Family Foundation, www.kff.org/racial-equity-and-health-policy/issue-brief/how-are-states-addressing-racial-equity-in-covid-19-vaccine-efforts/ (2021, accessed March 18, 2021).
Google Scholar53. Centers for Disease Control and Prevention. Prescription drug monitoring programs (PDMPs) , www.cdc.gov/drugoverdose/pdmp/states.html (2020, accessed 1 April 2021).
Google Scholar54. Finley, EP, Garcia, A, Rosen, K, et al. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res 2017; 17: 240.
Google Scholar | Crossref | Medline55. Rhodes, E, Wilson, M, Robinson, A, et al. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Services Res 2019; 19: 784.
Google Scholar | Crossref | Medline56. Bonar, EE, Coughlin, L, Roche, JS, et al. Prescription opioid misuse among adolescents and emerging adults in the United States: a scoping review. Prev Med 2020; 132: 105972.
Google Scholar | Crossref | Medline57. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS report: age of substance use initiation among treatment admissions ages 18 to 30 . Report, Rockville, MD, USA, July 2014.
Google Scholar58. Schepis, TS, Hakes, JK. Age of initiation, psychopathology, and other substance use are associated with time to use disorder diagnosis in persons using opioids nonmedically. Subst Abus 2017; 38: 407–413.
Google Scholar | Crossref | Medline59. Attridge, M, Cahill, T, Granberry, SW, et al. The national behavioral consortium industry profile of external EAP vendors. J Workplace Behav Health 2013; 28: 251–324.
Google Scholar | Crossref60. Kelly, JF, Bergman, B, Hoeppner, BB, et al. Prevalence and pathways of recovery from drug and alcohol problems in the United States population: implications for practice, research, and policy. Drug Alcohol Depend 2017; 181: 162–169.
Google Scholar | Crossref |